Literature DB >> 21037428

Extended liver resection for polycystic liver disease can challenge liver transplantation.

Béatrice Aussilhou1, Ghislaine Douflé, Catherine Hubert, Claire Francoz, Catherine Paugam, Valérie Paradis, Olivier Farges, Valérie Vilgrain, François Durand, Jacques Belghiti.   

Abstract

OBJECTIVE: In an attempt to refine the indications for liver resection (LR) for highly symptomatic polycystic liver disease (PLD), we focused on the characteristics, technical difficulties, postoperative outcome, and long-term follow-up of PLD patients who underwent either LR or liver transplantation (LT).
METHODS: Since 1995, among 72 patients with massive hepatomegaly, 45 patients underwent LR associated with contralateral cyst fenestration whereas 27 underwent LT associated with simultaneous kidney transplantations in 23. The LR group was characterized by absence of end-stage renal insufficiency, absence of ascites, and better nutrition status. In the LR group, the volumetry of the spared noncystic parenchyma was preoperatively assessed whereas pathological analysis focused on fibrosis and vascular congestion.
RESULTS: After LR, the mortality was nil and overall morbidity was 71%, including biliary leak in 20% and ascites in 42%. Persistent and massive ascites was observed in 8 patients who have undergone extensive resection and had significantly more frequently fibrosis on the analysis of their resected surgical specimens (P = 0.002). A volume of the remnant noncystic parenchyma less than 30% and the presence of vascular changes on the specimen were associated with higher risk of complications. The 5-year survival was 95% and among the 43 survivors, after a mean follow-up of 41 months, 36 (83%) patients stated that they were satisfied, with complete relief of symptoms in 30 (70%). After LT, the postoperative mortality was 15% and the overall morbidity was 85%, including 12 patients who required reoperation. Severe complications were more frequent in the presence of denutrition and preoperative ascites. The 5-year survival was 85% and after a mean follow-up of 36 months all survivors had complete relief of symptoms due to hepatomegaly.
CONCLUSIONS: In case of massive hepatomegaly from PLD without end-stage renal failure, LR should be considered first when preserved remnant liver volume represents at least 30% of the total volume liver in the absence of vascular changes or fibrosis.

Entities:  

Mesh:

Year:  2010        PMID: 21037428     DOI: 10.1097/SLA.0b013e3181fb8dc4

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  14 in total

1.  A case of a maintenance hemodialysis patient with autosomal dominant polycystic kidney disease who underwent living donor liver transplantation alone due to refractory liver cyst infection.

Authors:  Taro Akihisa; Ayami Ino; Hiroto Egawa; Yoshihito Kotera; Shunichi Ariizumi; Akiko Oomori; Shingo Yamashita; Yusuke Yamamoto; Ken Tsuchiya; Masakazu Yamamoto; Kosaku Nitta; Toshio Mochizuki
Journal:  CEN Case Rep       Date:  2018-06-28

2.  Hepatic cysts treated with percutaneous ethanol sclerotherapy: time to extend the indications to haemorrhagic cysts and polycystic liver disease.

Authors:  Julie Benzimra; Maxime Ronot; David Fuks; Mohamed Abdel-Rehim; Annie Sibert; Olivier Farges; Valérie Vilgrain
Journal:  Eur Radiol       Date:  2014-02-22       Impact factor: 5.315

3.  Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease.

Authors:  Lucas H P Bernts; Myrte K Neijenhuis; Marie E Edwards; Jeff A Sloan; Jenna Fischer; Rory L Smoot; David M Nagorney; Joost P H Drenth; Marie C Hogan
Journal:  Surgery       Date:  2020-05-08       Impact factor: 3.982

4.  Outcomes and Durability of Hepatic Reduction after Combined Partial Hepatectomy and Cyst Fenestration for Massive Polycystic Liver Disease.

Authors:  Fouad T Chebib; Amber Harmon; Maria V Irazabal Mira; Yeon Soon Jung; Marie E Edwards; Marie C Hogan; Patrick S Kamath; Vicente E Torres; David M Nagorney
Journal:  J Am Coll Surg       Date:  2016-01-14       Impact factor: 6.113

Review 5.  Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment.

Authors:  Luiz Fernando Norcia; Erika Mayumi Watanabe; Pedro Tadao Hamamoto Filho; Claudia Nishida Hasimoto; Leonardo Pelafsky; Walmar Kerche de Oliveira; Ligia Yukie Sassaki
Journal:  Hepat Med       Date:  2022-09-29

6.  Peri-operative challenges and long-term outcomes in liver transplantation for polycystic liver disease.

Authors:  Roberto Gedaly; Paige Guidry; Daniel Davenport; Michael Daily; Jens Ronsenau; Malay Shah; Michael A Cooper; Jonathan Hundley
Journal:  HPB (Oxford)       Date:  2012-09-21       Impact factor: 3.647

7.  Losartan supports liver regrowth via distinct boost of portal vein pressure in rodents with 90 % portal branch ligation.

Authors:  Kezhou Li; Xiaohong Qi; Jiaying Yang; Jianping Gong; Chunlu Tan; Qingjie Xia; Jieran Long; Zhongdin Wang
Journal:  Dig Dis Sci       Date:  2013-04-30       Impact factor: 3.199

8.  Clinical symptoms and sonographic follow-up after surgical treatment of nonparasitic liver cysts.

Authors:  Hubert Scheuerlein; Falk Rauchfuss; Julia Franke; Karin Jandt; Yves Dittmar; Gudrun Trebing; Utz Settmacher
Journal:  BMC Surg       Date:  2013-09-30       Impact factor: 2.102

9.  Assessing hepatomegaly: automated volumetric analysis of the liver.

Authors:  Marius George Linguraru; Jesse K Sandberg; Elizabeth C Jones; Nicholas Petrick; Ronald M Summers
Journal:  Acad Radiol       Date:  2012-02-22       Impact factor: 3.173

Review 10.  Management of portal hypertension and ascites in polycystic liver disease.

Authors:  Lucas H P Bernts; Joost P H Drenth; Eric T T L Tjwa
Journal:  Liver Int       Date:  2019-09-20       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.